Format

Send to

Choose Destination
Am J Clin Exp Urol. 2014 Oct 2;2(3):231-8. eCollection 2014.

Proinflammatory cytokine interleukin-6 in prostate carcinogenesis.

Author information

1
Experimental Urology, Department of Urology, Innsbruck Medical University Anichstrasse 35, A-6020 Innsbruck, Austria.

Abstract

Interleukin-6 (IL-6) is a multifunctional pro-inflammatory cytokine which is expressed in clinical specimens obtained from patients with prostate cancer and in multiple cell lines. IL-6 expression is regulated in prostate cancer by several oncogenes and tumor suppressors. IL-6 activates in prostate cancer pathways of Janus kinases/signal transducers and activators of transcription (STAT), mitogen-activated protein kinases, and phosphatidylinositol 3-kinase. In several tumor models, proliferative and anti-apoptotic effects were described, although androgen-sensitive prostate cancer cells LNCaP are inhibited by IL-6. IL-6 is also involved in regulation of neuroendocrine differentiation and angiogenesis in prostate cancer. IL-6 activation of the androgen receptor is important for tumor growth and differentiation. IL-6 activation of STAT3 is crucial for maintenance of the tumor progenitor cells phenotype. Suppressors of cytokine signaling inhibit permanent activation of STAT3, however they may have also IL-6-independent effects. Experimental therapies with aim to inhibit IL-6 signaling in prostate cancer were developed with the monoclonal antibody CNTO328. Although progression towards castration resistance was delayed by CNTO328 in a xenograft model, clinical monotherapies in patients with castration therapy-resistant disease with the antibody did not yield a satisfactory response.

KEYWORDS:

Prostate cancer; antibodies; apoptosis; interleukin; tumor progenitor cells

PMID:
25374925
PMCID:
PMC4219316

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center